NASDAQ:ZLAB

Zai Lab - ZLAB Stock Forecast, Price & News

$35.08

-2.97 (-7.81%)

(As of 09/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $34.49
▼
$37.00
50-Day Range: $35.08
▼
$51.69
52-Week Range: $22.51
▼
$110.61

Volume: 492,127 shs
Average Volume: 697,759 shs
Market Capitalization: $3.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $119.00

Zai Lab MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 239.2% Upside
$119.00 Price Target
Short Interest: Bearish
3.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.36
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.63) to ($4.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

1005th out of 1,097 stocks

Pharmaceutical Preparations Industry

500th out of 548 stocks

3.4

Analyst's Opinion

Consensus Rating
Zai Lab has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $119.00, Zai Lab has a forecasted upside of 239.2% from its current price of $35.08.
Amount of Analyst Coverage
Zai Lab has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.22% of the outstanding shares of Zai Lab have been sold short.
Short Interest Ratio / Days to Cover
Zai Lab has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Zai Lab has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Zai Lab does not currently pay a dividend.
Dividend Growth
Zai Lab does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZLAB.

0.9

News and Social Media Coverage

News Sentiment
Zai Lab has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Zai Lab this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zai Lab insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.26% of the stock of Zai Lab is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zai Lab are expected to grow in the coming year, from ($4.63) to ($4.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zai Lab is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zai Lab is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zai Lab has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

September 29, 2022 | finance.yahoo.com

Latest Push by Chinese Firms to Avoid US Delistings Falls Short

September 28, 2022 | finance.yahoo.com

A Chinese pharma plans fast expansion of Cambridge HQ

September 27, 2022 | finance.yahoo.com

Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment

September 27, 2022 | seekingalpha.com

Seagen partners with Zai Lab to introduce cervical cancer drug in China

September 27, 2022 | finance.yahoo.com

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

September 20, 2022 | finance.yahoo.com

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

September 17, 2022 | seekingalpha.com

ZLAB Zai Lab Limited

September 7, 2022 | reuters.com

Zai Lab Ltd

September 2, 2022 | finance.yahoo.com

“A Strong Power in Rapid Ascent”: 10 China Stocks in Ray Dalio’s Portfolio

August 28, 2022 | morningstar.com

Zai Lab Ltd ADR Repr 1 Shs

August 25, 2022 | stocknews.com

3 Healthcare Stocks Wall Street Expects to Soar Nearly 200%

August 23, 2022 | finance.yahoo.com

Zai Lab Announces Participation in September Investor Conferences

August 10, 2022 | nasdaq.com

Zai Lab (NASDAQ:ZLAB) shareholders are up 18% this past week, but still in the red over the last year

August 9, 2022 | finance.yahoo.com

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

August 8, 2022 | marketwatch.com

Zai Lab Shares Rise After Karuna Therapeutics Reports Positive KarXT Data

August 8, 2022 | seekingalpha.com

Karuna Therapeutics jumps 52% as schizophrenia trial meets key goal

August 8, 2022 | finance.yahoo.com

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

August 8, 2022 | finance.yahoo.com

Why Earnings Season Could Be Great for Zai Lab (ZLAB)

August 2, 2022 | finance.yahoo.com

US Audit Watchdog Insists on Full Access in China-Delisting Case

July 27, 2022 | finance.yahoo.com

Wall Street Analysts Think Zai Lab Limited Unsponsored ADR (ZLAB) Could Surge 145%: Read This Before Placing a Bet

July 25, 2022 | finance.yahoo.com

Qiming's Portfolio Company InventisBio Lists on STAR Market

July 24, 2022 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

July 19, 2022 | finance.yahoo.com

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

July 17, 2022 | finance.yahoo.com

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

July 13, 2022 | finance.yahoo.com

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings: 8/09/2022
Today: 9/30/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZLAB
CUSIP: N/A
CIK: 1704292
Web: www.zailaboratory.com
Phone: 862161632588
Fax: 86-21-6163-2570
Employees: 1,951
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $119.00
High Stock Price Forecast: $199.00
Low Stock Price Forecast: $64.00
Forecasted Upside/Downside: +239.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-704,470,000.00
Net Margins: -290.14%
Pretax Margin: -289.55%
Return on Equity: -38.53%
Return on Assets: -33.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.91
Quick Ratio: 7.77

Sales & Book Value

Annual Sales: $144.31 million
Price / Sales: 23.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.31 per share
Price / Book: 2.45

Miscellaneous

Outstanding Shares: 97,909,000
Free Float: 91,780,000
Market Cap: $3.43 billion
Optionable: Optionable
Beta: 1.00

Key Executives

Dr. Ying Du Ph.D. (Age 56)
Founder, Chairperson & CEO
Comp: $1.64M

Mr. Ki Chul Cho (Age 44)
Chief Financial Officer
Comp: $720.97k

Mr. Frazor Titus Edmondson III (Age 56)
Chief Legal Officer & Corp. Sec.
Comp: $829k

Dr. Harald Reinhart M.D. (Age 70)
Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
Comp: $845.94k

Dr. Alan Bart Sandler M.D. (Age 65)
Pres & Head of Global Devel. in Oncology
Comp: $1.19M

Mr. Joshua L. Smiley (Age 52)
Chief Operating Officer

Ms. Ann E. Beasley J.D.
Chief Compliance Officer

Ms. Danielle Halstrom
Sr. VP & Global Head of Communications

Dr. Ning Xu M.D. (Age 57)
Exec. VP & Head of Clinical Operations

Dr. Jonathan J. Wang M.B.A. (Age 40)
MBA, Ph.D., Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.
What is Zai Lab's stock price forecast for 2022?: 5 brokerages have issued 12 month price objectives for Zai Lab's shares. Their ZLAB share price forecasts range from $64.00 to $199.00. On average, they expect the company's share price to reach $119.00 in the next year. This suggests a possible upside of 239.2% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.
How have ZLAB shares performed in 2022?: Zai Lab's stock was trading at $62.85 at the start of the year. Since then, ZLAB stock has decreased by 44.2% and is now trading at $35.08.
View the best growth stocks for 2022 here.
When is Zai Lab's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ZLAB earnings forecast.
How were Zai Lab's earnings last quarter?: Zai Lab Limited (NASDAQ:ZLAB) announced its earnings results on Tuesday, August, 9th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by $0.49. The company had revenue of $48.18 million for the quarter, compared to analyst estimates of $46.78 million. Zai Lab had a negative trailing twelve-month return on equity of 38.53% and a negative net margin of 290.14%.
What other stocks do shareholders of Zai Lab own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?: (ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
What is Zai Lab's stock symbol?: Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
How do I buy shares of Zai Lab?: Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zai Lab's stock price today?: One share of ZLAB stock can currently be purchased for approximately $35.08.
How much money does Zai Lab make?: Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.43 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($5.55) on an earnings per share basis.
How many employees does Zai Lab have?: The company employs 1,951 workers across the globe.
How can I contact Zai Lab?: Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zai Lab - ZLAB Stock Forecast, Price & News

Zai Lab MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows